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Abstract
Purpose: To review brachytherapy use in recurrent head and neck carcinoma (RHNC) with focus on its efficacy 
and complication rates.
Material and methods: A literature search of PubMed, Ovid, Google Scholar, and Scopus was conducted from 1990 
to 2017. Publications describing treatment of RHNC with brachytherapy with or without surgery were included. The 
focus of this review is on oncologic outcomes and the safety of brachytherapy in the recurrent setting. 
Results: Thirty studies involving RHNC treatment with brachytherapy were reviewed. Brachytherapy as ad-
junctive treatment to surgical resection appears to be associated with an improved local regional control and overall 
survival, when compared with the published rates for re-irradiation utilizing external beam radiotherapy (RT) or 
brachytherapy alone. Safety data remains variable with different isotopes and dose rates with implantable brachyther-
apy demonstrating a tolerable side effect profile.
Conclusions: Although surgery remains a mainstay treatment for RHNC, intraoperative interstitial brachytherapy 
delivery as adjunctive therapy may improve the treatment outcome and may be associated with fewer complication 
rates as compared to reirradiation using external beam radiotherapy. Further investigations are required to elucidate 
the role of brachytherapy for RHNC.
J Contemp Brachytherapy 2018; 10, 5: 454–462 
DOI: https://doi.org/10.5114/jcb.2018.79399
Key words: cesium, head and neck cancer, recurrent.
Purpose
Head and neck carcinoma (HNC) continue to be a com-
monly diagnosed cancer with almost 50,000 new cases and 
almost 10,000 deaths each year [1]. More than 90% of HNC 
are classified as squamous cell carcinoma, and cases have 
increased by nearly 5,000 new patients over two years [2,3]. 
Patients with locally advanced disease generally are treat-
ed with an algorithm of surgical resection, radiotherapy 
(RT), and/or chemoradiotherapy with curative intent. Un-
fortunately, depending on subsite and stage, almost half of 
these advanced stage patients fail this approach in the first 
5 years [4,5]. The predominant pattern of recurrence is in 
a locoregional manner [5]. Surgical resection for these pa-
tients has become the mainstay of treatment in resectable 
cases, and re-irradiation as the only locoregional treatment 
modality for unresectable cases.
Brachytherapy with or without salvage surgery has 
often been used for this group of cancer patients with 
RHNC. Compared to external beam radiation therapy 
(EBRT) delivery systems, including intensity modulat-
ed radiation therapy (IMRT) and proton beam therapy, 
brachytherapy offers focused dose delivery and fewer 
early toxic effects, while minimizing adjacent non-cancer 
tissue toxicity, specifically in previously irradiated fields 
[5]. This protection of adjacent normal tissue can result in 
preservation of laryngeal and tongue function. Although 
brachytherapy has been utilized for recurrent head and 
neck cancer (RHNC) for years, its use has been limited 
due to availability of technical expertise, variable isotope 
implantation technical issues, and introduction of IMRT 
and other alternative EBRT modalities. Brachytherapy 
can be delivered via permanent implants (using low-dose-
rate brachytherapy or LDR or high-dose-rate brachyther-
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apy or HDR) or via removable catheters through which 
typically high activity radioisotopes are inserted (using 
HDR or pulsed-dose-rate brachytherapy or PDR) [6]. Per-
manent implants may be advantageous in patients with 
recurrence in irregular surfaces that are not suitable for 
catheter-based isotope delivery [7]. This review describes 
brachytherapy efficacy in recurrent primary HNC and re-
currence in neck disease, and potential complications of 
brachytherapy. We separated studies based on whether 
brachytherapy was the sole treatment or in conjunction 
with surgical tumor resection.
Material and methods
A literature search using PubMed, Ovid, Google 
Scholar, and Scopus was conducted. Databases were 
searched for the terms ‘recurrent head and neck cancer’ 
AND ‘brachytherapy’ between 1990 and 2017. Additional 
search terms included ‘Cesium-131’, ‘Iridium-192’, and 
‘Iodine-125’. The general criteria for the studies to be in-
cluded were publications describing brachytherapy use 
in recurrent HNC of various sites, with particular focus 
on treatment outcomes and complications. Publications 
involving 131Cs brachytherapy are also described. The 
search identified a total of 380 papers, with 350 papers 
being excluded after title and abstract screening. In 
these excluded papers, brachytherapy in recurrent HNC 
of various sites was not the chief focus. The remaining 
30 studies reported adequate information according to the 
criteria. Statistical analysis was also performed to com-
pare recurrence rates in studies, which used brachythera-
py with surgery versus brachytherapy alone.
Results
In the 30 reviewed studies, 95% (1,440 of 1,515 patients) 
had prior radiation therapy, making radiotherapy treat-
ment options limited. In 23 of these studies, brachyther-
apy was administered using Iridium-192 (192Ir) in 1,003 
patients, Iodine-125 (125I) in 131 patients, and Cesium-131 
(131Cs) in 35 patients. Seven studies did not explicitly 
state which type of isotope was used [8,9,10,11,12,13,14]. 
Brachytherapy was incorporated into treatment planning 
with or without salvage surgery in a combined modality 
approach. Occasionally, brachytherapy was also followed 
by further radiation therapy or chemotherapy. Reirradia-
tion with brachytherapy was used for local, locoregional, 
or nodal recurrence or neck disease and not for distant 
metastatic spread. As with most forms of reirradiation, 
the toxicity profile of brachytherapy includes neurologic 
toxicity, dysphagia, carotid artery rupture, skin necrosis, 
fistulas, and osteoradionecrosis [15,16]. These aspects 
and other considerations within the studies are described 
in further detail below.
Table 1. Overview of studies treating recurrent head and neck squamous cell carcinoma using brachytherapy 
alone
Author, Year N Brachytherapy Total dose Additional therapy Results Complications
Grimard,
2006 [5]
82 Ir 192; LDR ≥ 55 Gy Surgery (14),  
EBRT (3),  
Surgery + EBRT (6)
LC at 2 years: 37%
OS at 2 years: 33%
8.5% acute toxicity
22% late toxicity
Strnad,
2014 [8]
104 PDR 55 Gy or 24 Gy  
(when +EBRT)
Surgery (51%),  
EBRT (32%),  
Chemo (56%)
LC at 5 years: 82%
OS at 5 years: 21%
31% late toxicity 
Strnad,
2014 [12]
51 PDR 60 Gy or 27 Gy  
(when +EBRT)
EBRT (22%),  
Chemo (69%)
LC at 5 years: 57% 10% acute grade 3
29% late toxicity
Puthawala,
2001 [17]
220 Ir 192; LDR Median: 53 Gy Chemo (88) LC at 5 years: 51%
OS at 5 years: 20%
60% acute toxicity
27% late toxicity 
(65% of which had RT 
> 65 Gy)
Hepel,
2005 [18]
30 Ir 192; HDR Mean: 34 Gy Chemo (43%),  
EBRT (6%)
LC at 2 years: 67%
OS at 2 years: 37%
16% late grade 3-4 
toxicity
Jiang, 
2011 [19]
29 I 125; LDR, 
US-guided
Median: D90 130 Gy Not mentioned LC at 2 years: 35%
OS at 2 years: 28%
No carotid rupture 
or soft tissue/bone 
necrosis
Glatzel,
2002 [37]
90 Ir 192; HDR Median: 17.5 Gy Not mentioned Median: OS 6 Mo 7% late grade 3-4
Zhu,
2013 [32]
19 I 125; LDR, 
US or CT-guided
Median: D90 131 Gy Not mentioned LC at 2 years: 27.5%
OS at 2 years: 18%
No grade 4 or  
5 toxicity
Meng,
2012 [38]
17 I 125; LDR, 
US or CT-guided
Median: D90 126 Gy Not mentioned LC at 2 years: 50%
OS at 2 years: 24%
No grade 3 or  
4 toxicity
Wiegand,  
2013 [39]
12 Ir 192; HDR Mean: 20-33 Gy Not mentioned Median: OS 8.5 Mo No serious complica-
tions
Ir 192 – Iridium 192; I 125 – Iodine 125; Gy – Gray; LDR – low-dose-rate; HDR – high-dose-rate; PDR – pulsed-dose-rate; US – ultrasound; CT – computed tomography; 
EBRT – external beam radiation therapy; RT – radiotherapy; LC – local control; OS – overall survival 
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Brachytherapy for local disease:  
with and without salvage surgery
Re-irradiation with brachytherapy has been used as 
an option for resectable and unresectable RHNC cases. 
While salvage surgery in general is favored, its use may 
be limited by the extent of disease and the cancer’s inti-
mate anatomic relationship to adjacent structures. Low-
dose-rate (LDR), high-dose-rate (HDR), and pulsed-dose-
rate (PDR) brachytherapy can be used as monotherapy 
alone or adjuvantly with salvage surgery. Tables 1 and 2 
provide details of all studies using brachytherapy alone 
and with surgery, respectively. Some of these studies are 
further described below. 
The use of brachytherapy alone was associated with 
lower local control (LC) and overall survival (OS) rates. In 
a study by Puthawala et al. [17], 220 patients with RHNC 
received salvage brachytherapy using LDR interstitial 
Iridium-192 (192Ir) implants. They achieved 2-, 5-, and 
10-year disease-free survival (DFS) rates of 60%, 33%, and 
22%, respectively [17]. Hepel et al. [18] found similar re-
sults using HDR 192Ir brachytherapy with DFS at 2 years 
being 45% and OS at 1 and 2 years, 56% and 37%, respec-
tively. Strnad et al. [8] found that their LC rates at 2, 5, and 
10 years were 92.5%, 82.4%, and 58.9%, respectively, with 
a 5-year OS of 21% using PDR brachytherapy. Jiang et al. 
[19] used LDR 125I ultrasound-guided permanent seeds in 
patients with RHNC ineligible for salvage surgery, and 
achieved LC rates at 1, 2, and 3 years of 53.1%, 34.8%, and 
17.4%, and OS rates at 1, 2, and 3 years of 54.1%, 27.5%, 
and 27.5%, respectively. 
In the recurrent setting, surgical resection remains 
the foundation of treatment for resectable disease, when 
looking at oncologic outcomes. In a study by Grimard et 
al. [5], brachytherapy was used as monotherapy in 22 of 
45 patients and with surgery in 20 of 45 patients [5]. While 
not statistically significant, salvage surgery with adju-
vant brachytherapy led to better locoregional control [5]. 
Narayana et al. [9] studied patients with recurrent HNC 
with 18/30 receiving surgery and HDR, 3/30 receiving 
EBRT and HDR, and 9/30 receiving HDR alone. There 
was improved local control in patients who received sal-
vage surgery versus those without surgery: 88% vs. 40% 
[9]. In a study by Rudzianskas et al. [20], 43% of patients 
Table 2. Overview of studies treating recurrent head and neck squamous cell carcinoma using surgery with 
brachytherapy 
Author, year N Brachytherapy Total dose Surgical  
resection
Results Complications
Henderson, 
2016 [6]
23 Ir 192; HDR 
Cs-131; LDR
Mean: 21 Gy
Mean: 81 Gy
Yes Not mentioned 50% toxicity in HDR pts
30% toxicity in LDR pts
Narayana, 
2007 [9]
30 HDR 34 Gy (+ surgery)
20 Gy (+ EBRT)
40 Gy (only BT)
60% Yes
40% No
LC at 2 years: 71% 
(88% + surgery,  
40% – surgery)
OS at 2 years: 63%
33% grade 2-3 toxicity
Martinez- 
Fernandez, 
2017 [10]
63 HDR Total: 32 or 40 Gy Yes LC at 15 years: 41%
OS at 15 years: 12%
51% grade ≥ 3 toxicity
Schiefke, 
2008 [11]
13 HDR Median: 30 Gy Yes OS at 2 years: 65%
LR failure in 38%
69% acute toxicity
31% late toxicity
Scala, 
2013 [13]
76 HDR Median rate: 1,200 cGy Yes LC at 2 years: 62%
OS at 2 years: 42%
No grade 3-4 toxicity
Rudzianskas, 
2012 [20]
30 Ir 192; HDR Total: 30 Gy 43% Yes
57% No
LC at 2 years: 77%
OS at 2 years: 62%
Non-surgical group:
LC at 2 years: 47%
OS at 2 years: 35%
10% acute grade 2-3
10% late grade 2-4
Park, 
1991 [21]
35 I 125; LDR Mean rate: 
8,280 cGy
Yes OS at 2 years: 38% 
OS at 5 years: 29%
36% acute and/or late 
toxicity
Pellizzon,
2005 [22]
42 Ir 192; HDR Median: 24 Gy Yes Crude LC 57%
OS at 5 years: 52.5%
19% acute and/or late 
toxicity
Pham, 
2015 [23]
18 Cs 131; LDR Median: 80 Gy Yes OS at 18 mos: 45%
LR failure in 33%
11% grade 3 toxicity
Teckie, 
2013 [41]
57 Ir 192; HDR Median: 15 Gy Yes OS at 3 years: 32%
LR failure in 46%
37% grade 3
No grade 4-5 toxicity
Perry, 
2010 [42]
34 Ir 192; HDR Median: 15 Gy Yes OS at 2 years: 55% 29% grade 3-4 toxicity
Ir 192 – Iridium 192; I 125 – Iodine 125; Cs 131 – Cesium 131; Gy – Gray; LDR – low-dose-rate; HDR – high-dose-rate; EBRT – external beam radiation therapy; 
BT – brachytherapy; LC – local control; LR – locoregional; OS – overall survival 
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had surgery and HDR with 192Ir, while 57% had HDR 
alone. Patients who received surgery and brachythera-
py had improved 2-year local control rates (77%) and OS 
rates (62%) versus those with brachytherapy alone (47%, 
35%, respectively) [20]. These differences in locoregional 
control underscore the overall benefit of surgical resec-
tion in the recurrent setting. 
In a study by Park et al. [21], LDR 125I seeds were im-
planted in patients with RHNC who all underwent sal-
vage surgery. DFS at 1, 2, and 5 years was 64%, 47%, and 
41%, respectively, with a 5-year no evidence of disease 
(NED) in patients (29%) [21]. Pellizzon et al. [22] stud-
ied patients with RHNC treated with surgery and HDR 
192Ir brachytherapy with or without further EBRT and 
found the OS at 5 and 8 years to be 52.5% and 48.1%. 
Martinez-Fernandez et al. [10] followed previously irra-
diated RHNC patients treated with salvage surgery and 
perioperative HDR brachytherapy for 15 years, finding 
a 15-year LRC rate of 41.2% and 15-year OS rate of 11.6%. 
Pham et al. [23] showed that in selected patients, 131Cs in-
traoperative seeds with salvage surgery achieved 1-, 2-, 
and 3-year LC rates of 69%, 62%, and 52%, respectively. 
Looking to historic data of re-irradiation using the 
standard or hyperfractionated IMRT combined with sys-
temic chemotherapy has demonstrated a 2-year survival 
of 10-25% [24,25]. The previously discussed studies us-
ing surgery plus brachytherapy reported a 5-year overall 
survival of 33-67%, showing encouraging progress over 
EBRT plus chemotherapy. 
We performed a statistical analysis of the studies to 
evaluate locoregional recurrence in RHNC patients re-
ceiving brachytherapy and surgery vs. brachytherapy 
alone. Logistic regression was used to compare recur-
rence rates, and generalized estimating equations (GEE) 
methods were used to account for clustering within the 
study. In studies where recurrence rates were not explic-
itly stated, recurrence rates were extrapolated based on 
the local and locoregional control rates. For the primary 
analysis, the rate of locoregional recurrence was 38.8% 
(143/369) in the surgery with brachytherapy group and 
49.0% (329/671) in the brachytherapy alone group. The 
estimated odds ratio was 0.66 (95% CI: 0.38-1.12; p = 0.13).
Brachytherapy for nodal disease
Many studies also have demonstrated brachytherapy 
use in RHNC with regional failure in the cervical lymph 
nodes. Table 3 portrays the details of these studies. In the 
study by Bartochowska et al. [26], patients with unresect-
able isolated cervical lymph node recurrence had PDR or 
HDR with 192Ir via catheters. Local control rates at 1 and 
2 years were 31.7% and 19% [26]. Huang et al. [27] 
achieved better results in 31 patients with RHNC with 
neck metastases unmanageable with other techniques, 
achieving LC rates of 64.5% and 45.1% at 1 and 2 years. In 
74 patients with inoperable recurrent lymphadenopathy, 
Tselis et al. [28] showed OS rates of 42%, 19%, and 6% at 
1, 2, and 3 years, respectively. 
In the study by Teudt et al. [14], patients with RHNC 
underwent revision surgery and perioperative HDR for 
their recurrent neck metastases. These patients were 
found to have 78% and 67% OS at 2 and 5 years, respec-
tively, with a median survival of 65 months [14]. Nutting 
et al. [29] also looked at patients with recurrent neck dis-
ease undergoing LDR brachytherapy alone, with resec-
tion, or with resection and flap surgery. Locoregional 
control at 2 years in those who had brachytherapy alone 
was 0%, while those who also had a surgery with or with-
out a flap had improved LRC, 37% or 33%, respectively 
[29]. For the neck disease statistical analysis, the rate of 
locoregional recurrence was 30.9% (42/136) in the sur-
gery with brachytherapy group and 49.0% (149/304) in 
the brachytherapy alone group. The estimated odds ratio 
was 0.46 (95% CI: 0.25-0.86; p = 0.015). 
Complications
Due to the nature of the radioactive isotopes, 
brachytherapy is associated with various radiation expo-
sure concerns. However, these radiation effects appear to 
be improved in terms of functional organ preservation 
and reduced irradiation to surrounding normal tissues 
compared to EBRT or IMRT (Quon). Toxicity is com-
monly monitored using the Radiation Toxicity Oncology 
Group (RTOG) common toxicity criteria [30]. Radiation 
safety procedures, including the use of lead shields and 
gloves, may be appropriate when handling specific radio-
isotope implants, which is based on a number of factors 
including isotope, total source activity, and implant loca-
tion [31]. The recommended limit of radiation exposure 
to staff personnel based on federal regulation is 50 mSv/
year for “stochastic effects”, e.g., cancer or genetic effects, 
defined as “ones in which the probability of occurrence 
increases with increasing absorbed dose, but the severity 
does not depend on the magnitude of the absorbed dose” 
[31]. In some cases associated with specific radioisotopes, 
patients were isolated in order to reduce personnel and 
family radiation exposure, and were required to stay in 
the hospital longer. 
Toxicity complications related to brachytherapy have 
been explored in various studies using 192Ir and 125I and 
usually involve necrosis, dysphagia, or fistulas. Tables 
1-3 include toxicity rates for studies reviewed. In a review 
by Kasperts et al. [15], 17% (120/704) of patients devel-
oped soft tissue necrosis and 2% (15/704) developed oro-
cutaneous fistulas. Another 2% of patients suffered from 
hemorrhage or carotid blowouts and another 3% devel-
oped osteoradionecrosis [15]. In the study by Grimard et 
al. [5], acute toxicity occurred in 15.6% of patients and late 
toxicity in 40%, with 4 patients developing grade 2 or 3 
radionecrosis and 7 patients experiencing dysphagia. In 
Zhu et al.’s study [32], only one patient had a grade 1 skin 
reaction, with no patients suffering from soft tissue ne-
crosis or other complications. Henderson et al. [6] looked 
at patients who underwent HDR or LDR brachytherapy 
and neck dissection with or without flap coverage. There 
were complications in 50% of HDR patients and 29.4% of 
LDR patients, with only 3 of 22 patients receiving flaps 
having complications (2 HDR, 1 LDR) [6]. Martinez-Fer-
nandez et al. [10] found RTOG grade 3 or greater toxicities 
in 50.8% of patients, with 17 cases needing further opera-
tions due to fistula (6), wound dehiscence (4), bleeding (3), 
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or other (4). Notably, many forms of brachytherapy did 
not use permanent implantable seeds but temporary 
catheters for the purpose of low-dose or high-dose-rate 
brachytherapy. Hemorrhage after catheter or tube re-
moval was reported [15]. 
In contrast, Pham et al. [23] reported similar or lower 
rates of acute and chronic toxicity with 131Cs as compared 
to studies using 192Ir and 125I. Only 2 of 18 patients had 
grade 3 toxicity and none had grade 4-5 toxicity. When 
present, grade 1-2 complications were primarily derma-
titis and hoarseness [23]. The risk to healthcare personnel 
and close family members has been minimized with iso-
topes like 131Cs compared to some previous brachyther-
apy isotopes, which required special precautions [31]. 
Many prior studies portrayed the effects of 125I and 192Ir 
brachytherapy on RHNC, but fewer studies have ex-
plored the use of permanent 131Cs. 131Cs offers a high-
dose-rate, focused delivery, and less radiation exposure 
to adjacent tissues, personnel, and the patient’s family 
[23,31]. Compared to 125I, 131Cs has a dose-rate several 
times higher because of its similar energy but much low-
er half-life (9.69 days) [33]. This allows for 131Cs to deliver 
~90% of its dose in a 33-day period, unlike 32% of the 
dose delivered by 125I in that time frame [33]. This longer 
period of time exposes staff and family to potentially in-
creased radiation doses and may require special precau-
tions. Suture strands containing 131Cs seeds can be fixed 
0.5-1 cm apart within the tumor bed or come in a pre-im-
bedded mesh (Figure 1) [31]. With brachytherapy done 
during salvage surgery, flaps also may help to prevent 
seed migration and dosimetry alterations. After implan-
tation, seed placement can be monitored radiographically 
by generating a post-implant plan and toxicity monitored 
using RTOG common toxicity criteria [30]. In a study by 
Parasher et al. [31], 28 patients received a median number 
of twenty 131Cs seeds implanted at 0.5-1 cm distance for 
lung or HN cancer, with a median seed activity of 2.4 U. 
Median radiation exposure rate at the skin and at 1 me-
ter was 0.43 mSV and 0.002 mSv, respectively. Minimum 
measurable radiation dose for OSL badge and TLD ring 
was 1 mrem and 30 mrem [31]. These minimal dose levels 
allow for patients to interact with family members and 
caregivers without special precautions like special lead 
protective equipment or isolation. 
Discussion
Treatment options for RHNC remain limited. Many 
patients have undergone previous surgeries with or 
without radiation, chemotherapy, immunotherapies, 
Table 3. Overview of studies treating recurrent squamous cell carcinoma as neck disease 
Author, year N Brachytherapy Total dose Surgical  
resection
Results Complications
Bartochowska, 
2015 [26] 
60 Ir 192;
PDR (49 pts) or
HDR (11 pts)
Median: 20 Gy or 24 Gy No LC at 2 years: 27%
OS at 2 years: 19%
33% acute toxicity
12% late toxicity 
Huang, 
2016 [27] 
31 I 125; LDR, 
CT-guided
Mean: D90 101 Gy No LC at 2 years: 45%
OS at 2 years: 45%
No grade 3 or 4 toxicity
Tselis, 
2011 [28] 
74 Ir 192;
HDR, CT-guided 
Median: 30 Gy No LC at 2 years: 67% 
OS at 2 years: 19%
5% acute grade 3-4 toxicity
8% late grade 3-4 toxicity
Kolotas, 
2007 [43] 
49 Ir 192; 
HDR, CT-guided
Total: 30 Gy or 36 Gy No LC at 19 mos: 69%
OS at 2 years: 31%
OS at 3 years: 6% 
16% acute grade 2-3 toxicity
Bollet, 
2001 [44] 
84 Ir 192; LDR Mean: 56.5 Gy No LC at 2 years: 31%
LC at 5 years: 0%
OS at 2 years: 13%
OS at 5 years: 1%
35% grade 3-4 toxicity
7% grade 5 (death)
Brachytherapy combined with surgical resection 
Teudt, 
2016 [14] 
9 HDR Mean: 27 Gy Yes OS at 2 years: 78%
OS at 5 years: 67%
No grade 3 or 4 toxicity
Kupferman, 
2007 [24] 
22 Ir 192; LDR Median: 60 Gy Yes RC at 2 years: 67%
OS at 5 years: 46%
14% acute grade 3-4 toxicity
18% late grade 3-4 toxicity
Nutting,
2006 [29] 
72 Ir 192; LDR Total: 60 Gy Yes in 66
No in 6
LC at 5 years: 23%
OS at 5 years: 23%
Non-surgical group:
LC at 2 years: 0%
OS at 2 years: 0%
15% grade 3-4 toxicity
Cornes, 
1996 [40] 
39 Ir 192; LDR Mean: 49.6 Gy Yes LC at 1 yr: 63%
OS at 2 yrs: 38%
5% acute grade 3-4 toxicity
23% late grade 3-4 toxicity
Ir 192 – Iridium 192; I 125 – Iodine 125; Gy – Gray; LDR – low-dose-rate; HDR – high-dose-rate; PDR – pulsed-dose-rate; CT – computed tomography; LC – local control; 
RC – regional control; OS – overall survival 
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and/or combination therapies, which limit retreatment 
options with radiation in general and EBRT in partic-
ular. The most common current treatment for curative 
intent is salvage surgery but may not be feasible for all 
cases [34,35,36]. Despite wide margins and G0 resection, 
locoregional recurrence still thwarts the curative efforts 
in the recurrent setting. Adding focused radiation di-
rected at the resection margin during salvage surgery, 
while sparing toxicity to surrounding tissue, is in theory 
promising. 
Brachytherapy has shown to be an effective treatment 
option with acceptable toxicity profiles for RHNC. When 
using brachytherapy alone, the reported LR control rates 
and OS rates at 2 years range from 27.5-92.5% and 18.2-
43%, respectively [5,8,12,17,18,19,32,37,38,39]. Some stud-
ies have revealed brachytherapy to have enhanced and 
improved results when combined with salvage surgery 
[9,20,29,40]. Salvage surgery with brachytherapy as ad-
junctive therapy has 2-year LR control rates and OS rates 
ranging from 62-88% and 38-65.3%, respectively [6,9,10,11, 
13,20,21,22,23,41,42]. Studies by Narayana et al. and Rud-
zianskas et al. even compared LC and OS rates at 2 years 
between those who received brachytherapy with and 
without surgery and found improved rates in those also 
receiving surgery [9,20]. Although our analysis comparing 
locoregional recurrence rates of patients receiving surgery 
with brachytherapy vs. brachytherapy alone was not sta-
tistically significant, there was a trend of 38.8% vs. 49.0%. 
For brachytherapy use in patients with neck disease, LC 
and OS rates at 2 years had likewise fair responses, with 
rates ranging from 27.3-67% and 13-78%, respectively 
[14,24,26,27,28,29,40,43,44]. Many of these studies had re-
current HNC with neck metastases that appeared inopera-
ble or unmanageable with other therapies. Yet, analysis in 
these neck disease patients did show a statistically signifi-
cant difference (p = 0.015) in locoregional recurrence rates 
(30.9% vs. 49.0%) between the combined treatment group 
and brachytherapy alone group, respectively. 
In comparison, a review by Goodwin [34] described 
outcomes using salvage surgery alone, the most common 
salvage treatment. The weighted average of OS at 3 years 
was 37% (range: 28-80%) and at 5 years was 36.4% (range: 
23-55%) [34]. Goodwin [34] also reported the weighted 
average of disease-free survival (DFS) rates at 2 years: 
36.3% (range: 0-59%). Moreover, a literature review by 
Strojan et al. [35] examined local control and survival 
rates using conventional EBRT techniques and newer 
EBRT techniques like IMRT, with or without surgery, in 
recurrent HNC. Locoregional control rates and OS rates 
at 2 years using conventional radiation techniques with 
salvage surgery ranged from 13-74% (average: 38%) 
and 21-67% (average: 42.5%), respectively [35]. Newer 
RT techniques like IMRT have been showing better out-
comes. For example, a study by Lee et al. [36] did show 
that IMRT had improved LR recurrence-free survival at 
2 years over conventional RT techniques (52% vs. 20%) 
but did not significantly improve OS rates. In general, 
for patients receiving IMRT (with or without salvage 
Fig. 1. A) Post-operative radiographic Cesium-131 seed 
dosimetry. B) Cesium-131 seed placement intra-opera-
tively
A B
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Fig. 2. Proposed algorithm for treating recurrent head and neck squamous cell carcinoma
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Consider systemic 
therapy
Resectable
Non-resectable
Consider Chemo/IT 
+ IMRT
Primary treatment 
including EBRT  
< 12 months prior
Primary treatment 
including EBRT  
> 12 months prior
Consider systemic 
therapy ± locore-
gional treatment
With  
locoregional failure 
Without  
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Standard  
chemotherapy 
regimen
Immunotherapy  
(i.e. PD-1 inhibitors)
surgery), LR control and OS rates at 2 years ranged from 
27-77% and 19.5-58%, respectively [35,45]. 
Similarly, to some brachytherapy studies, patients re-
ceiving reirradiation (either using conventional or newer 
RT techniques) with salvage surgery had improved out-
comes. One phase III randomized trial by Janot et al. [46] 
divided patients into receiving salvage surgery alone or 
with adjuvant full-dose reirradiation with chemotherapy. 
Patients in the radiation arm (using conventional RT) had 
significantly improved LR control and DFS rates but no 
significant change in OS rates at 2 years [46]. Likewise, 
a study by Takiar et al. [47] showed improved disease 
control and survival outcomes using adjuvant IMRT af-
ter surgery (vs. surgery alone) in HNSCC patients with 
a 5-year OS rate of 57%.
Complications appear less frequent or severe com-
pared to EBRT techniques including IMRT. In some 
brachytherapy studies, complication rates ranged as 
high as 50-60% for acute grade 1-2 toxicities including 
mucositis, dermatitis, hoarseness, infection, or hema-
toma [12,14,17,26,27]. Late grade 3-4 toxicities included 
complications like fistula, soft tissue necrosis, ORN, dys-
phagia, fibrosis, trismus, severe hemorrhage, and wound 
dehiscence, with rates ranging from 7-51% [9,10,12,17, 
18,20,21,28,29,37,40,42]. In the study by Takiar et al. [47] 
using IMRT for re-irradiation, there was a 5-year grade 
≥ 3 toxicity rate of 48%, with three patients dying due 
to radiation toxicity. However, the majority of patients 
who now are receiving their first round of radiation with 
IMRT may likely have fewer overall complications, if or 
when they receive reirradiation. Literature is limited at 
this time to support this theory but will likely be shown 
in coming years. 
We propose an algorithm to help guide treatment op-
tions for patients with RHNC (Figure 2). For example, for 
patients with resectable locoregional recurrence, consid-
er surgical resection followed by brachytherapy or EBRT 
with or without chemotherapy or immunotherapy. Using 
brachytherapy versus external radiation techniques like 
IMRT may depend on the timing, type of previous RT, 
and location of recurrence. Despite the safety, ease of use, 
and promising efficacy advantages of 131Cs, the use for 
specific RHNC populations requires further investiga-
tion. Unfortunately, the majority of published literature 
is retrospective, and the patient cohorts and treatment 
approaches used are very heterogeneous. In theory, com-
bining a radiation boost to salvage surgery may provide 
dual therapy with less radiotherapy toxicity. 131Cs with 
salvage surgery and other combinations with immuno-
therapy may offer a viable treatment pathway for RHNC 
for some patients and should be studied in future clinical 
trials. Our institution has recently been studying 131Cs 
brachytherapy in RHNC with preliminary promising re-
sults. At this time, HDR and PDR appear to be the current 
techniques of choice due to optimization of implant do-
simetry and geometric sparing with and reduced treat-
ment time. 
Conclusions
Treatment options for RHNC remain challenging. 
Although brachytherapy alone can be used to treat 
RHNC, locoregional control rates and overall survival 
rates are higher when brachytherapy is used as adjunc-
tive therapy to salvage surgery. These rates remain com-
parable or improved when brachytherapy is utilized in 
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neck disease with or without surgery. Regardless of the 
type of radiotherapy used, these patients continue to 
face significant risks for recurrence and complications 
including fistula formation, carotid rupture, dyspha-
gia, osteoradionecrosis, and prolonged hospital stay 
[9,10,20,21,42,48,49,50]. With the recent introduction of 
isotopes with more favorable properties, complication 
rates have the potential to be lower while preserving lo-
cal regional control rates. 
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